Circulating tumour DNA (ctDNA) burden quantified through low-pass whole genome sequencing as an early pharmacodynamic biomarker of therapeutic response in patients enrolled on phase 1 trials.

Authors

null

Aaron C. Tan

National Cancer Centre Singapore, Singapore, Singapore

Aaron C. Tan , Yu Amanda Guo , Chowdhury Rafeed Rahman , Tira Jing Ying Tan , Stephanie Pei Li Saw , David Dai-Wee Lee , Justina Yick Ching Lam , Wai Meng David Tai , Sharmaine Jia Xin Tan , Matilda Ya Wen Boey Ya Wen , Christine Carolyn , Mei Xuan Yong , Pamela Shi Ying Kuan , Hanae Camille Carrie , Jia Chi Yeo , Iain Bee Huat Tan , Giuseppe Curigliano , Matthew C.H. Ng , Daniel Shao-Weng Tan , Anders Skanderup

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics

Sub Track

Other Technology and Innovations

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 23)

DOI

10.1200/GO.2023.9.Supplement_1.23

Abstract #

23

Poster Bd #

A3

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Annual Meeting

Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.

Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.

First Author: Abdulazeez Salawu

First Author: Wei Guo

Poster

2023 ASCO Annual Meeting

Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.

Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.

First Author: Pashtoon Murtaza Kasi